Key Access Pathways and Bottlenecks for Medicines in LMICs

32 Pages

This report analyzes access to both recently launched and established medicines across low- and middle-income countries (LMICs). It assesses registration, inclusion on essential medicines lists, reimbursement, and in-country availability. Findings reveal major delays and gaps, particularly for newer therapies, driven by regulatory, financing, and infrastructure barriers. The report highlights opportunities to strengthen access through faster registration, updated national lists, and improved procurement and reimbursement mechanisms.

Join for free to read

Case Study Mankind Pharma improves operational efficiencies with SUSE in…

Report Innovative Funding for Medicines in Latin America

Report The Use of Medicines in the U.S.

White Paper Industry pathways to net zero - Decarbonisation in manufacturing

More from IQVIA

Report Innovative Funding for Medicines in Latin America

Report The Use of Medicines in the U.S.

Report Defining Essential Innovative Medicines and Measuring their Use…

Report Developing Efficient Patient Referral Pathways for Radioligand…

Report

Key Access Pathways and Bottlenecks for Medicines in LMICs

Key Access Pathways and Bottlenecks for Medicines in LMICs

You Might Also Like

More from IQVIA